drug transporters
Clinically Relevant Drug Transporters Conference
August 09 by Pharma IQChoosing which clinically relevant drug transporters to study is not straightforward. Having said this, knowing which are necessary for regulatory approval and which are simply ‘nice to...
Trends in Computational Toxicology & Critical Success Factors for Transporter Studies- Full Interview with Tobias Noeske
June 27 by Pharmaceuticals & Biotechnology Editor
In this exclusive interview Tobias Noeske, Associate Principal Scientist from AstraZeneca, speaks to Andrea Charles from Pharma IQ, about the recent trends in computational toxicology and...
Trends in Computational Toxicology & Critical Success Factors for Transporter Studies
May 30 by Andrea CharlesIn this exclusive interview Tobias Noeske, Associate Principal Scientist from AstraZeneca, speaks to Andrea Charles from Pharma IQ. Noeske describes how AstraZeneca are reducing compound...
Pharma Industry Report: A Global Guide to Clinically Relevant Drug Transporters
May 24 by Pharmaceuticals & Biotechnology Editor
In this 10 page pharma industry report we look at drug transporter outsourcing, intelligent drug development applied to clinically relevant drug transporters and drug transporters in ADME....
Improving patient compliance, oral bioavailability and drug uptake using computational biology and PEPT1- Dr Simon Newstead
May 15 by Gerald ClarkeDr Simon Newstead is Lecturer in Membrane Protein Crystallography at the University of Oxford. In this interview, he explores why uptake transporters are important in drug development and he explore...
Global Guide to Drug Transporters
October 15 by Pharmaceuticals & Biotechnology Editor
Pharma IQ in conjunction with the 3rd Annual Clinically Relevant Drug Transporters prepared this Global Guide to Drug Transporters, the definitive resource for professionals in the drug transportati...
FDA Draft Guidance 2012: Drug Interaction Studies- Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations
May 29 by Pharmaceuticals & Biotechnology Editor
This guidance provides recommendations for sponsors of new drug applications (NDAs) and biologics license applications (BLAs) for therapeutic biologics regulated by CDER regarding in vitro and in vi...
Genome-Wide Assessment of the Carriers Involved In The Cellular Uptake of Drugs: A Model System in Yeast
May 29 by Pharmaceuticals & Biotechnology Editor
Abstract Background: The uptake of drugs into cells has traditionally been considered to be predominantly via passive diffusion through the bilayer portion of the cell membrane. The recent recogn...
Clinically Relevant Drug Transporters: Understanding DDI with a View to Better Prediction and Control
December 15 by Andrea CharlesHow is the industry seeking to understanding DDI with a view to better prediction and control? How has the current technology landscape changed following the publication of the ITC white paper?...
Clinically Relevant Drug Transporters: What Progress is to be Expected in 2012?
December 08 by Pharma IQResearch into drug transporters forms an increasingly important part of the non-clinical development phase, with new fields such as pharmacogenomics offering new approaches to an area that is increa...
ITC to clarify the ITC Whitepaper on Clinically Relevant Drug Transporters in London
April 06 by Pharma IQ NewsThis June, Mikko Neimi, ITC member, will meet with European industry experts at Pharma IQ's Clinically Relevant Drug Transporters to discuss the ITC Whitepaper and the imminent FDA guidelines....
What Are the Advantages and Disadvantages of Human Embryonic Kidney (HEK) Cells for the Analysis of Uptake Transporters?
March 04 by Rebecca MaschkeDr. Jörg König from the Institute for Experimental and Clinical Pharmacology and Clinical Toxicology at Friedrich-Alexander-University Erlangen-Nürnberg, Germany, speaks to Rebecca Ma...
